Microbix announces the voting results from the Annual Meeting of Shareholders of the Company (the “Meeting”) which was held on March 25, 2026.

Microbix announces that it is presenting results of novel QUANTDx™ reference materials designed to emulate real-life human papillomavirus (“HPV”) patient-samples and thereby better support the validation of molecular (e.g., “PCR”) tests for infection. Microbix is presenting at EUROGIN, an international conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Vienna, Austria from March 18 to 21, 2026.

Microbix announces that the contract development and manufacturing organization (“CDMO”) engaged by its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has modernized production methods for the active ingredient (i.e., “Drug Substance”) of Kinlytic® urokinase (“Kinlytic”), a biologic for dissolving blood clots.

Microbix announces the issuance of stock options under its shareholder-approved stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

KRC Insights published an update report on Microbix’s FQ1 2026 financial results. All of KRC’s previous research reports, including this latest one.

Microbix reports results for its first quarter of fiscal 2026 ended December 31, 2025 (“Q1”). Results for Q1 demonstrated the Company’s efforts to rebuild revenues back above its breakeven point following two client setbacks in mid-2025, with revenue growth of 13% compared to Q4 fiscal 2025. Q1 revenues and net loss were as-budgeted for fiscal 2026.